HER2 Biomarker in Colon Cancer | Know Your Biomarker
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - ScienceDirect
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression | PLOS ONE
Representative picture of HER2/neu immunohistochemistry of colorectal... | Download Scientific Diagram
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models | Journal of Experimental & Clinical Cancer Research | Full Text
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer | SpringerLink
Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer | Virchows Archiv
Cancers | Free Full-Text | Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-1-full.png "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
Pathology Outlines - HER2 colon
Comprehensive assessment of HER2 alteration in a colorectal cancer coh | CMAR
Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
Anti-HER2 Agents Gain Ground in Colorectal Cancer
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology
Life | Free Full-Text | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
Les thérapies HER2 pour les patients atteints de mCCR
HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria | Journal of Cancer Research and Clinical Oncology
HER2 expression and copy number alterations in colorectal cancer (CRC).... | Download Scientific Diagram
miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer | British Journal of Cancer
Fulfilling the potential of HER2-targeting in colorectal cancer: update on detection and management - YouTube
Q&A column - CAP TODAY
HER2/neu testing in primary colorectal carcinoma | British Journal of Cancer
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-5-2x.jpg "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
